TL;DR

PD-1/VEGF bispecifics rose rapidly to prominence following ivonescimab’s swift regulatory success in China, catalyzing global investment and a wave of FDA-track development programs. The biological rationale is compelling—VEGF inhibition can enhance immune checkpoint activity, and IO + VEGF combinations already have clinical precedent. However, most of the enthusiasm rests heavily on data from a single molecule and geography. As programs transition into global Phase 3 settings, the evidentiary bar rises significantly, particularly in competitive frontline solid tumors where overall survival (OS) remains the regulatory gold standard. Recent global data showing PFS benefit without definitive OS separation underscores the uncertainty. While the mechanism holds real promise, late-stage regulatory and translational risks appear underappreciated. In short, PD-1/VEGF bispecifics represent strong biological conviction but still-limited global regulatory proof, and strategic decisions should reflect that asymmetry.

When Biology, Capital, and Narrative Collide

Few oncology mechanisms have moved from obscurity to global prominence as rapidly as dual PD-1/VEGF inhibition in a single molecular entity. What was, until recently, a largely China-centric development story has, in under three years, become one of the most aggressively pursued immuno-oncology strategies globally—drawing capital, partnerships, and late-stage development bets from both biopharma and financial markets.

At the center of this momentum sits ivonescimab (AK112), Akeso’s PD-1/VEGF bispecific antibody, whose clinical and regulatory success in China catalyzed an industry-wide re-rating of the mechanism. However, as the program transitions from a China-optimized development environment into the far more stringent and precedent-driven FDA regulatory ecosystem, cracks are beginning to emerge between perceived momentum and demonstrated global replicability.

This paper examines how the PD-1/VEGF bispecific story took hold, why enthusiasm has outpaced evidence in FDA-track development, and why—despite real biological promise—the current late-stage risk profile remains materially underappreciated.

The Biological Rationale: Elegant, Intuitive, and Hard to Argue Against

From a mechanistic standpoint, the appeal of combining immune checkpoint blockade (PD-1) with angiogenesis inhibition (VEGF) is obvious and well supported:

• VEGF is immunosuppressive, impairing dendritic cell maturation, T-cell trafficking, and effector function.
• Anti-VEGF therapy can normalize tumor vasculature, improve immune infiltration, and synergize with checkpoint inhibition.
• Clinically, IO + VEGF combinations (e.g., PD-1 + bevacizumab, PD-1 + TKIs) have repeatedly demonstrated additive or synergistic effects across tumor types.

The bispecific thesis goes one step further:

If PD-1 and VEGF inhibition are synergistic as combinations, why not deliver them in a single molecule with fixed stoichiometry, optimized exposure, and simplified clinical development?

This logic is sound. The problem is not biology—it is translation, comparability, and regulatory proof.

China as the Spark: Ivonescimab’s Rapid Ascent

Ivonescimab’s rise is inseparable from its China-first development strategy.

• May 2024: First approval in China via HARMONi-A (NCT05184712)
• April 2025: Second approval via HARMONi-2 (NCT05499390)

Both approvals were achieved in NSCLC, a highly competitive indication globally, but one in which China’s regulatory framework allows:

• Greater reliance on PFS
• Earlier approvals with immature OS
• Local comparator standards that may differ from US/EU expectations

The clinical data was compelling within this context: strong PFS gains, manageable safety, and a narrative of “best-of-both-worlds” IO biology. Importantly, ivonescimab did not just succeed—it outperformed expectations relative to PD-1 monotherapy benchmarks, creating the perception of a step-change rather than an incremental advance.

Capital followed quickly.

From Breakthrough to Bandwagon: The Explosion of PD-1/VEGF Assets

In the three years following ivonescimab’s clinical readouts:

• Eight PD-1/VEGF bispecific assets entered FDA-track development
• All clinical programs initiated within the last ~36 months
• All programs are active—none approved, none discontinued
• Only two assets have reached Phase 3:
  • Akeso/Summit’s ivonescimab
  • Pfizer’s SSGJ-707

This is a classic early-signal amplification pattern:

1. A single asset succeeds in a permissive regulatory environment
2. The mechanism is validated in principle
3. Capital, not attrition, becomes the dominant filter
4. Late-stage risk accumulates silently

Crucially, ivonescimab itself dominates the Phase 3 evidence base. Despite the growing pipeline, the field is effectively extrapolating from one molecule, one geography, one sponsor experience.

The Global Test: HARMONi and the OS Problem

That extrapolation met reality with the global HARMONi Phase 3 trial (NCT06396065).

• Primary endpoints: PFS and OS
• Outcome:
  • PFS met
  • OS showed only a positive trend, not statistical significance

The market reaction was immediate and instructive: Summit’s stock declined sharply upon disclosure, reflecting a reassessment of regulatory probability rather than biological promise.

From an FDA perspective, this matters enormously.

In frontline or competitive solid tumor settings:

• OS remains the gold standard
• PFS-only approvals are increasingly rare without:
  • Clear unmet need
  • Large effect size
  • Or a compelling surrogate justification

Despite this, Summit submitted a FDA BLA in January 2026, signaling confidence—or at least willingness—to test the boundaries of regulatory discretion.

This is not unprecedented, but it is high-risk behavior.

Why China Success May Not Be Fully Portable

The divergence between China and US outcomes should not be dismissed as noise. Several structural factors are at play:

1. Comparator and Standard-of-Care Drift: US trials increasingly benchmark against optimized PD-1 backbones, combination regimens, and sequencing strategies that compress incremental benefit.

2. Post-Progression Therapy Confounding: OS separation is harder to demonstrate in markets with broad access to subsequent lines of therapy—particularly immunotherapy re-challenge.

3. Trial Powering Assumptions: China-based programs often assume larger effect sizes that do not replicate in more heterogeneous global populations.

4. Regulatory Philosophy: China rewards speed and access; the FDA rewards durability and certainty.

None of these invalidate the mechanism—but they raise the bar.

What the Data Is Quietly Saying: Elevated Late-Stage Risk

Intelligencia’s Probability of Technical and Regulatory Success (PTRS) modeling flags most Phase 3 PD-1/VEGF programs as high-risk, reflecting a confluence of factors:

• Limited OS precedent
• Heavy reliance on a single clinical success narrative
• Compressed development timelines
• Mechanistic crowding in already competitive indications

Importantly, the absence of discontinued programs is not reassurance—it is a sign that natural attrition has not yet occurred.

History suggests it will.

So Is PD-1/VEGF a Fad—or the Next IO Backbone?

The honest answer is: neither—and possibly both.

• The biology is real
• The China data is real
• The commercial upside is real

But so are the risks:

• Regulatory skepticism without OS
• Difficulty reproducing effect sizes globally
• Portfolio crowding before true differentiation is established

Ivonescimab may yet secure FDA approval—regulatory outcomes are probabilistic, not deterministic. However, current evidence suggests that clinical success in China should be viewed as enabling, not confirming, global approvability.

For executives, portfolio managers, and BD leaders, the implication is clear:

PD-1/VEGF bispecifics are a high-conviction mechanism with low-conviction late-stage proof—at least for now.

Capital allocation, partnering strategy, and pipeline valuation should reflect that asymmetry.

Bottom Line: Proceed With Eyes Open

The PD-1/VEGF story is not over. But it is entering its most unforgiving chapter—the one where biology meets regulation, and where narrative must give way to endpoints.

In that transition, discipline—not hype—will separate durable winners from expensive lessons.

For more tailored, data-rich insights, let’s talk.